Paraoxonase cluster polymorphisms are associated with sporadic ALS

Background: Paraoxonases (PONs) are involved in the detoxification of organophosphate pesticides and chemical nerve agents. Due to a reported possible twofold increased risk of ALS in Gulf War veterans and the associations of PON1 polymorphisms with the neurologic symptom complex of the Gulf War syndrome, the authors investigated the association between sporadic ALS (SALS) and PON gene cluster variants in a large North American Caucasian family–based and case-control cohort (N = 1,891). Methods: Clinically definite and probable ALS was diagnosed according to the revised El Escorial criteria, exclusion of family history of ALS, and SOD1 mutation analysis. Single nucleotide polymorphism (SNP) genotyping was done using TaqMan assays on ABI7900HT. Data were analyzed using SPSS, Haploview, FBAT, and THESIAS. Results: A haploblock of high linkage disequilibrium (LD) spanning PON2 and PON3 was associated with SALS. The SNPs rs10487132 and rs11981433 were in strong LD and associated with SALS in the trio (parents-affected child triad) model. The association of rs10487132 was replicated in 450 nuclear pedigrees comprising trios and discordant sibpairs. No association was found in case-control models, and their haplostructure was different from that of the trios with overall reduced LD. Resequencing identified an intronic variant (rs17876088) that differentiated between detrimental and protective SALS haplotypes. Conclusion: This study demonstrates evidence of significant association of variants in the Paraoxonase gene cluster with sporadic ALS and is compatible with the hypothesis that environmental toxicity in a susceptible host may precipitate ALS.

[1]  K. Lunetta,et al.  Polymorphisms in the PON gene cluster are associated with Alzheimer disease. , 2006, Human molecular genetics.

[2]  T. Delmonte,et al.  Evaluation of the Paraoxonases as Candidate Genes for Stroke: Gln192Arg Polymorphism in the Paraoxonase 1 Gene Is Associated With Increased Risk of Stroke , 2005, Stroke.

[3]  R. Sunahara,et al.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M , 2005, Journal of Lipid Research.

[4]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[5]  C. Armon.  Excess incidence of ALS in young Gulf War veterans , 2004, Neurology.

[6]  J. Haines,et al.  Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis , 2004, Neurogenetics.

[7]  Elias Zintzaras,et al.  Association of paraoxonase 1 gene polymorphisms with risk of Parkinson′s disease: a meta-analysis , 2004, Journal of Human Genetics.

[8]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[9]  D. Tregouet,et al.  A new algorithm for haplotype‐based association analysis: the Stochastic‐EM algorithm , 2004, Annals of human genetics.

[10]  J. Danesh,et al.  Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies , 2004, The Lancet.

[11]  B. La Du,et al.  Pharmacogenetics of paraoxonases: a brief review , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  S. Grambow,et al.  Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations , 2003, Neurology.

[13]  M. Rose.  Gulf War service is an uncertain trigger for ALS , 2003, Neurology.

[14]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Mathews,et al.  Setback for an Alzheimer’s disease vaccine , 2003, Neurology.

[16]  M. Hotopf,et al.  Paraoxonase in Persian Gulf War Veterans , 2003, Journal of occupational and environmental medicine.

[17]  R. Haley.  Gulf war syndrome: narrowing the possibilities , 2003, The Lancet Neurology.

[18]  C. Carlson,et al.  Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. , 2003, Pharmacogenetics.

[19]  L. Costa,et al.  Polymorphisms of Paraoxonase (PON1) and Their Significance in Clinical Toxicology of Organophosphates , 2003, Journal of toxicology. Clinical toxicology.

[20]  J. Loscalzo,et al.  Paraoxonase 192 Gln→Arg Polymorphism: An Independent Risk Factor for Nonfatal Arterial Ischemic Stroke Among Young Adults , 2002, Stroke.

[21]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[22]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[23]  D. Shih,et al.  Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  A. Tward,et al.  Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. , 2000, Pharmacogenetics.

[25]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Mackness,et al.  Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. , 2000, Biochemical and biophysical research communications.

[27]  C. Furlong.  PON1 status and neurologic symptom complexes in Gulf War veterans. , 2000, Genome research.

[28]  Xin Xu,et al.  Implementing a unified approach to family‐based tests of association , 2000, Genetic epidemiology.

[29]  R. Haley,et al.  Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. , 1999, Toxicology and applied pharmacology.

[30]  T. Standiford,et al.  On the physiological role(s) of the paraoxonases. , 1999, Chemico-biological interactions.

[31]  D. Shih,et al.  The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. , 1999, Chemico-biological interactions.

[32]  S. Scherer,et al.  Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. , 1998, Gene.

[33]  P. Durrington,et al.  Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon , 1997, British journal of pharmacology.

[34]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[35]  E. Green,et al.  Structural organization of the human PON1 gene. , 1996, Genomics.

[36]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[37]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[38]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[39]  M. Pericak-Vance,et al.  Linkage analysis in familial amyotrophic lateral sclerosis , 1989, Neurology.

[40]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[41]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .